Group items tagged

American global healthcare company, Viatris, has launched a new rapid self-test for qualitative detection of antibodies developed after Covid-19 vaccinations. The firm is going to market the Covid-19 Neutralising IgG Serological self-test, manufactured by PRIMA Lab SA, in the UK market, which would check presence of neutralising antibodies after vaccination. The presence of antibodies indicates that a person has had an immune response to the Covid-19 vaccine, and not that protective immunity has been acquired. The self-test that can be performed easily at home with a small blood sample, delivers results in just 10 minutes and has a recommended retail price of sub £20. After two doses of the Covid-19 vaccine, the self-test has shown a seroconversion rate of 98.3 per cent for the Pfizer vaccine, 98.5 per cent for the AstraZeneca vaccine and 95.2 per cent for the Moderna vaccine. It recommended that the test be performed at least 14 days after completing the vaccination cycle.

British drugmaker GSK said on Tuesday (December 7) its antibody-based Covid-19 therapy with US partner Vir Biotechnology is effective against all mutations of the new Omicron coronavirus variant, citing new data from early-stage studies. The data, yet to be published in a peer-reviewed medical journal, shows that the companies' treatment, sotrovimab, is effective against all 37 identified mutations to date in the spike protein, GSK said in a statement. Last week, another pre-clinical data showed that the drug had worked against key mutations of the Omicron variant. Sotrovimab is designed to latch on to the spike protein on the surface of the coronavirus, but Omicron has been found to have an unusually high number of mutations on that protein. "These pre-clinical data demonstrate the potential for our monoclonal antibody to be effective against the latest variant, Omicron, plus all other variants of concern defined to date by the WHO," GSK chief scientific officer Hal Barron said.

Antibody Sequencing has been widely used in the research and development of antibody field. In order to meet with the biotechnical industry needs, Creative Biolabs established a solid platform for DNA sequencing of both IgG and IgM types of monoclonal antibodies produced by mouse and rat hybridoma cell lines. The sequences of a monoclonal antibody are important for patent protection and therapeutic approval...

DVD-IgG is one type of bispecific antibody format, which is generated from two parental mAbs by placing two variable domains from one parental antibody onto the heavy chain and the light chain of another parental antibody, instead of one variable domain. The variable domain pairs can be derived from whole human, mouse or rat mAbs with phage/yeast display libraries. And the short peptides derived from the N-termini of CH1 or CL link the outer variable domain (VD1) and the inner variable domain (VD2) together. The DVD-IgG retains the antigen-binding specificity, affinity, and biologic activities from its both parental antibodies, therefore, all of its four variable domains are functional. Many different DVD-IgGs have been designed and manufactured for treating complex diseases with multiple mediators contributing to overall disease pathogenesis.

The name coronavirus is derived from the Latin word corona meaning crown, Coronaviruses are a large family of viruses that infects the lungs

HIV can attack T-cells (SUPER important cells that protect your body from disease). When these cells killed off, your immune system weakens, and without T-cells, the human body cannot produce antibodies. All you can do is take medication to reduce the concentration of the virus to decrease the likelihood of transmission. For more information visit our website: https://drpounders.com/ or Call Us at 214-520-8833

HIV can attack T-cells (SUPER important cells that protect your body from disease). When these cells killed off, your immune system weakens, and without T-cells, the human body cannot produce antibodies. All you can do is take medication to reduce the concentration of the virus to decrease the likelihood of transmission. For more information visit our website: https://drpounders.com/ or Call Us at 214-520-8833

AstraZeneca said its antibody cocktail against Covid-19 would - unlike its vaccine - be priced commercially as it negotiates supply contracts with governments around the globe. "We are looking at a commercial pricing strategy. That is part of our negotiations with governments," Iskra Reic, Astra's executive vice president for vaccines and immune therapies, said in a media call on Thursday. She added that the group's main objective was to make the shot affordable and broadly available.

British drugmaker AstraZeneca says it's confident that its new version of COVID-19 antibody treatment could protect immunocompromised patients against all known virus variants. Laboratory studies show the antibody, called AZD3152, neutralises all known variants of COVID-19 and AstraZeneca has support from regulators to make the treatment available by the end of this year, the company's vaccines head Iskra Reic said on Tuesday (April 18). AstraZeneca plans, pending more positive data and regulatory approval, to make the antibody available by the end of 2023. These types of therapies are most needed for people with compromised immune systems, either because of underlying conditions or because they are undergoing immune suppressing treatments. They account for nearly 2% of the global population. AstraZeneca's AZD3152, it new COVID-19 antibody, was acquired through a $157 million deal last year with British biotech start-up RQ Bio. The British drugmaker will likely make future investments like its current partnerships with RQ Bio but did not have any deals to announce, said Reic, a long-time AstraZeneca executive who has led the company's vaccines and immune therapies unit since it was formed in late 2021, during the pandemic.